Predilife Stock

Predilife EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Predilife (ALPRE.PA) as of Aug 11, 2026 is -3.12. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -3.24 — a change of -3.80% (higher).

EV/EBIT

-3.12

YoY

-3.80%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Predilife is 2026 -3.12 . EV/EBIT (Enterprise Value to EBIT) of Predilife was 2025 -3.24 . It decreases by -3.80% higher compared to the previous year.

The Predilife EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-4.68 base
Jan 1, 2020
-4.96 base
Jan 1, 2021
-3.47 base
Jan 1, 2022
-2.69 base
Jan 1, 2023
-2.66 base
Jan 1, 2024
-3.40 base
Jan 1, 2025 (e)
-2.26 base
Jan 1, 2026 (e)
-0.82 base
YEARPRICE-TO-EBIT
2026 est -0.82
2025 est -2.26
2024 -3.40
2023 -2.66
2022 -2.69
2021 -3.47
2020 -4.96
2019 -4.68
2018 -5.30
2017 -
2016 -
Access this data via the Eulerpool API

Predilife Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Predilife's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Predilife's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Predilife's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Predilife grows earnings faster than its peers.

Predilife Stock analysis

What does Predilife do? Predilife SA is a company specializing in predictive medicine. It was founded in Switzerland in 2011 and has since been based in Marseille, France. The company currently has around 50 employees, most of whom are scientists and doctors. The idea for Predilife SA came from the realization that many diseases can be prevented if they are detected and treated in advance. As most diseases also have a genetic component, Predilife SA focuses on the development of tests that calculate individual disease risk based on individual genetics. The business model of Predilife SA is based on the development and sale of predictive genetic tests for various diseases. The company works with health insurance companies, insurance companies, companies, as well as directly with end customers. The company believes that predictive tests represent an opportunity for many people to detect diseases early and take appropriate preventive measures. The company offers predictive tests for a range of diseases, including cancer, cardiovascular diseases, neurodegenerative diseases, and diabetes. The tests are based on state-of-the-art molecular diagnostic methods that allow for the identification of genetic changes that increase individual disease risk. The tests are conducted in specialized laboratories and interpreted by qualified doctors and geneticists. Predilife SA operates four different divisions and offers a range of predictive tests for each division: Division 1: Cancer prevention This division focuses on tests for common types of cancer such as breast, colon, and prostate cancer. The tests assess the individual risk of developing cancer and help optimize prevention and surveillance measures. Division 2: Cardiovascular diseases This division offers tests that assess the individual risk of cardiovascular diseases such as heart attack or stroke. The results are used to take targeted preventive measures. Division 3: Neurological diseases This division develops tests for neurodegenerative diseases such as Alzheimer's or Parkinson's. The results help determine individual risk and take appropriate preventive measures. Division 4: Diabetes This division offers tests that assess the individual risk of type 2 diabetes. The results are used to take targeted preventive measures. In addition to predictive tests, Predilife SA operates its own research department that focuses on the development of new predictive tests and the further development of existing tests. The company collaborates with leading scientists and institutions worldwide. Overall, Predilife SA aims to make predictive medicine accessible to as many people as possible. The company relies on state-of-the-art technologies and high professional competence. Predilife is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Predilife stock

EV/EBIT (Enterprise Value to EBIT) of Predilife is -3.12 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Predilife changed from -3.24 to -3.12, representing a -3.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Predilife since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Predilife with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Predilife

All Key Metrics — Predilife